Pentostatin therapy for steroid-refractory acute graft versus host disease: identifying those who may benefit

[1]  I. Yakoub-Agha,et al.  A phase 3 randomized trial comparing inolimomab vs usual care in steroid-resistant acute GVHD. , 2017, Blood.

[2]  P. Chiusolo,et al.  Extracorporeal Photopheresis for Treatment of Acute and Chronic Graft Versus Host Disease: An Italian Multicentric Retrospective Analysis on 94 Patients on Behalf of the Gruppo Italiano Trapianto di Midollo Osseo. , 2016, Transplantation.

[3]  T. Braun,et al.  Combination Therapy for Graft-versus-Host Disease Prophylaxis with Etanercept and Extracorporeal Photopheresis: Results of a Phase II Clinical Trial. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[4]  F. Foss,et al.  The use of basiliximab–infliximab combination for the treatment of severe gastrointestinal acute GvHD , 2016, Bone Marrow Transplantation.

[5]  J. Donnelly,et al.  Combination Therapy with Inolimomab and Etanercept for Severe Steroid-Refractory Acute Graft-versus-Host Disease. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[6]  C. Lengerke,et al.  Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey , 2015, Leukemia.

[7]  B. Djulbegovic,et al.  Extracorporeal photopheresis in steroid-refractory acute or chronic graft-versus-host disease: results of a systematic review of prospective studies. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[8]  R. Itzykson,et al.  Alemtuzumab for severe steroid-refractory gastrointestinal acute graft-versus-host disease. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[9]  K. Myers,et al.  The successful use of alemtuzumab for treatment of steroid‐refractory acute graft‐versus‐host disease in pediatric patients , 2014, Pediatric transplantation.

[10]  J. Lipton,et al.  Limited benefit of pentostatin salvage therapy for steroid‐refractory grade III‐IV acute graft‐versus‐host disease , 2013, Clinical transplantation.

[11]  A. Bosi,et al.  Extracorporeal photopheresis for the treatment of acute and chronic graft‐versus‐host disease in adults and children: best practice recommendations from an Italian Society of Hemapheresis and Cell Manipulation (SIdEM) and Italian Group for Bone Marrow Transplantation (GITMO) consensus process , 2013, Transfusion.

[12]  M. Robin,et al.  Extracorporeal photopheresis versus anticytokine therapy as a second-line treatment for steroid-refractory acute GVHD: a multicenter comparative analysis. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[13]  J. Wingard,et al.  First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[14]  K. Liu,et al.  Basiliximab for the treatment of steroid-refractory acute graft-versus-host disease after unmanipulated HLA-mismatched/haploidentical hematopoietic stem cell transplantation. , 2011, Transplantation proceedings.

[15]  T. Luft,et al.  Pentostatin for treatment of steroid-refractory acute GVHD: a retrospective single-center analysis , 2011, Bone Marrow Transplantation.

[16]  D. Berry,et al.  Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. Gramatzki,et al.  Therapy of steroid-refractory acute GVHD with CD52 antibody alemtuzumab is effective , 2011, Bone Marrow Transplantation.

[18]  J. Pidala,et al.  Pentostatin as rescue therapy for glucocorticoid-refractory acute and chronic graft-versus-host disease. , 2010, Annals of transplantation.

[19]  J. Perkins,et al.  Sirolimus for treatment of steroid-refractory acute graft-versus-host disease , 2010, Bone Marrow Transplantation.

[20]  J. Perkins,et al.  Mycophenolate mofetil for the management of steroid-refractory acute graft vs host disease , 2010, Bone Marrow Transplantation.

[21]  A. Rademaker,et al.  Evaluation of pentostatin in corticosteroid-refractory chronic graft-versus-host disease in children: a Pediatric Blood and Marrow Transplant Consortium study. , 2009, Blood.

[22]  M. Pasquini,et al.  Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. , 2009, Blood.

[23]  P. Veys,et al.  Improved Survival and Preserved Antiviral Responses After Combination Therapy With Daclizumab and Infliximab in Steroid-refractory Graft-Versus-Host Disease , 2009, Journal of pediatric hematology/oncology.

[24]  C. Solano,et al.  Alemtuzumab as treatment of steroid-refractory acute graft-versus-host disease: results of a phase II study. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[25]  R. Storb,et al.  Initial therapy of acute graft-versus-host disease with low-dose prednisone does not compromise patient outcomes. , 2009, Blood.

[26]  H. Deeg,et al.  Therapy with mycophenolate mofetil for refractory acute and chronic graft-versus-host disease , 2009, Bone Marrow Transplantation.

[27]  A. Ibatici,et al.  Extracorporeal photopheresis for the treatment of steroid refractory acute GVHD , 2008, Bone Marrow Transplantation.

[28]  S. Giralt,et al.  Alemtuzumab for the treatment of steroid-refractory acute graft-versus-host disease. , 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[29]  Allen R. Chen,et al.  Phase II study of pentostatin in patients with corticosteroid-refractory chronic graft-versus-host disease. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  M. Perales,et al.  Long-term follow-up of patients treated with daclizumab for steroid-refractory acute graft-vs-host disease , 2007, Bone Marrow Transplantation.

[31]  H. Deeg,et al.  A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease. , 2007, Blood.

[32]  F. Locatelli,et al.  Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft‐versus‐host disease following allogeneic hematopoietic stem cell transplantation , 2007, American journal of hematology.

[33]  G. Hill,et al.  Combination antithymocyte globulin and soluble TNFα inhibitor (etanercept) +/− mycophenolate mofetil for treatment of steroid refractory acute graft-versus-host disease , 2006, Bone Marrow Transplantation.

[34]  A. Bacigalupo,et al.  Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulin. , 2006, Blood.

[35]  A. Fischer,et al.  Inolimomab in Steroid-Refractory Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation: Retrospective Analysis and Comparison with Other Interleukin-2 Receptor Antibodies , 2005, Transplantation.

[36]  E. Thiel,et al.  Efficacy of the interleukin‐2 receptor antagonist basiliximab in steroid‐refractory acute graft‐versus‐host disease , 2005, British journal of haematology.

[37]  T. Buchler,et al.  Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease , 2005, Annals of Hematology.

[38]  M. Grever,et al.  Pentostatin in steroid-refractory acute graft-versus-host disease. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  N. Callander,et al.  Denileukin diftitox for the treatment of steroid-resistant acute graft-versus-host disease. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[40]  J. Ritz,et al.  Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. , 2004, Blood.

[41]  B. Andersson,et al.  Tumor necrosis factor- (cid:1) blockade for the treatment of acute GVHD , 2004 .

[42]  N. Lee,et al.  Different efficacy of mycophenolate mofetil as salvage treatment for acute and chronic GVHD after allogeneic stem cell transplant. , 2004, European journal of haematology.

[43]  B. Andersson,et al.  Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. , 2004, Blood.

[44]  R. Fanin,et al.  Infliximab treatment for steroid-refractory acute graft-versus-host disease. , 2004, Haematologica.

[45]  L. Morris,et al.  Infliximab for steroid‐refractory acute GVHD: A case series , 2003, American journal of hematology.

[46]  B. Dörken,et al.  Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation , 2002, Bone Marrow Transplantation.

[47]  J. Wagner,et al.  Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[48]  M. Zahurak,et al.  Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[49]  J. Wagner,et al.  Early antithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[50]  H. Deeg,et al.  SIROLIMUS (RAPAMYCIN) FOR THE TREATMENT OF STEROID-REFRACTORY ACUTE GRAFT-VERSUS-HOST DISEASE1 , 2001, Transplantation.

[51]  R. Vij,et al.  Treatment of steroid-resistant acute graft-versus-host disease with anti-thymocyte globulin , 2001, Bone Marrow Transplantation.

[52]  M. Kiehl,et al.  Treatment of steroid refractory acute and chronic graft‐versus‐host disease with daclizumab , 2001, British journal of haematology.

[53]  K. Cleary,et al.  Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. , 2000, Blood.

[54]  D. Weisdorf,et al.  Treatment of moderate and severe acute GVHD after allogeneic bone marrow transplantation. , 1994, Transplantation.

[55]  A. Ho,et al.  Long‐term follow‐up of patients with hairy cell leukaemia treated with pentostatin: lymphocyte subpopulations and residual bone marrow infiltration , 1993, British journal of haematology.

[56]  O. Bagasra,et al.  Adenosine‐deaminase‐associated immunodeficiency. I. Differential sensitivities of lymphocyte subpopulations exposed to 2‐deoxycoformycin in vivo , 1992, Clinical and experimental immunology.

[57]  D. Weisdorf,et al.  Acute graft-versus-host disease following unrelated donor marrow transplantation: failure of conventional therapy. , 1992, Bone marrow transplantation.

[58]  J. Kersey,et al.  RISK FACTORS FOR ACUTE GRAFT‐VERSUS‐HOST DISEASE IN HISTOCOMPATIBLE DONOR BONE MARROW TRANSPLANTATION , 1991, Transplantation.

[59]  R. Storb,et al.  A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment. , 1990, Blood.

[60]  M. Grever,et al.  Immunosuppressive effects of pentostatin. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  R. Smialowicz,et al.  Selective immunotoxic effects in mice treated with the adenosine deaminase inhibitor 2'-deoxycoformycin. , 1987, Immunopharmacology.

[62]  D. S. Gordon,et al.  Inhibition of adenosine deaminase leads to enhanced antibody responses in the mouse. , 1983, Cellular immunology.

[63]  P. Neiman,et al.  CLINICAL MANIFESTATIONS OF GRAFT‐VERSUS-HOST DISEASE IN HUMAN RECIPIENTS OF MARROW FROM HL‐A-MATCHED SIBLING DONOR,S , 1974, Transplantation.